Semax

Semax is a synthetic heptapeptide that has been studied primarily in certain Eastern European contexts for potential neuroprotective, cognitive, and neurovascular effects.

Outside these regions, semax is often discussed in experimental and wellness-oriented communities rather than mainstream neurology guidelines.

Proposed mechanisms for semax include modulation of neurotrophic factors, antioxidant systems, and cerebral blood flow, as well as effects on certain neurotransmitter systems.

These hypotheses are drawn from preclinical and limited clinical studies, and their clinical impact is still being clarified.

In some settings, semax has been investigated or used in relation to cerebrovascular events, cognitive dysfunction, or stress-related conditions. The strength and regulatory standing of these uses differ by region.

In many jurisdictions, semax is not an approved therapy and is instead encountered in research or non-regulated markets.

Reported effects include local irritation with nasal formulations and nonspecific symptoms such as headache or mood changes. Long-term safety, especially with off-label use, has not been fully characterized.

Semax is a heptapeptide analog of ACTH(4-10) used primarily as a nasal spray for cognitive and neuroprotective effects.

This information summarizes commonly discussed practices. The 1.0% concentration is often reserved for acute stroke indications in clinical settings (Russia), while 0.1% is for cognitive support.

Formulation is the practical dividing line in the Semax world. The intranasal solution, supplied at 0.1% or 1.0% (1 mg or 10 mg of peptide per millilitre), is the form used in every published clinical study, including the 6,000 mcg/day regimen in the 110-patient stroke rehabilitation trial (Gusev et al. 2018). Lyophilized powder sold internationally for reconstitution and subcutaneous injection is the form most buyers actually encounter, and no clinical study has used it.

Semax is frequently grouped with, and sometimes sold alongside, selank — an anxiolytic peptide from the same Russian institute — and with racetams and other nootropics. Those pairings are marketing conventions rather than studied combinations: no published trial has evaluated Semax with a second agent, so a stack has neither an efficacy nor an interaction profile to reason from.

Research on semax includes preclinical models and clinical studies in select populations, with endpoints such as cognitive performance, neurologic recovery, and neuropsychological measures.

The heterogeneity of this literature and regional differences in practice make it important to review primary studies and expert commentary rather than relying solely on high-level summaries.

For deeper dives on this peptide, see:

• Semax benefits and areas of interest
• Semax side effects and safety context
• Semax dosing concepts (educational)
• Semax research and evidence overview

Is Semax approved anywhere? Yes, in Russia, where it is a registered medicine used in neurology. It has no FDA or EMA authorisation, and no regulator outside Russia and neighbouring states has evaluated it. A national registration reflects that regulator's evidentiary standard, which in this case accepted trials that were not double-blind.

Does Semax actually improve cognition in healthy people? No published controlled trial has tested that. The human studies enrolled stroke survivors and patients with cerebrovascular insufficiency — for example, 110 post-stroke patients in whom semax raised plasma BDNF and was associated with faster Barthel index recovery (Gusev et al. 2018), and 187 patients with cerebrovascular insufficiency in whom the authors reported fewer strokes and transient ischemic attacks (Gusev, Skvortsova and Chukanova 2005). Neither design was blinded, and neither involved healthy adults.

How does Semax work? It is an analogue of the ACTH(4-10) fragment with a proline-glycine-proline tail that resists enzymatic breakdown and removes the parent hormone's effect on the adrenal cortex. In rat basal forebrain, labelled Semax showed specific, calcium-dependent binding with a dissociation constant near 2.4 nM, and intranasal doses of 50 and 250 mcg/kg raised BDNF protein there within 3 hours — but not in the cerebellum (Dolotov et al., J Neurochem 2006). Increased neurotrophic signalling is the leading hypothesis for its effects, not a demonstrated cause of them.

Why is Semax a nasal spray rather than an injection? Because that is the route it was developed and studied for. In rats, intranasal Semax reached brain tissue within 2 minutes, with roughly 80% arriving intact before rapid degradation to the tripeptide Pro-Gly-Pro (Shevchenko et al. 2006). Injectable research powder sold online has no equivalent pharmacokinetic or clinical data, so intranasal figures cannot be converted to it.

Is Semax the same as Selank? No. Both came out of the same Russian research programme and are often sold together, but selank is a tuftsin analogue studied for anxiety, while Semax is an ACTH fragment studied for neuroprotection and cognition. No trial has evaluated them in combination.